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Objective: To investigate the neurometabolite level changes according to synapsin III gene 
rs133945G.A and rs133946C.G polymorphisms by using magnetic resonance spectroscopy 
(MRS) in patients with attention-deficit hyperactivity disorder (ADHD).
Methods: Fifty-seven adults diagnosed with ADHD were recruited for the study. The partici-
pants were examined by single-voxel 1H MRS when medication naïve and 30 minutes after 
oral administration of 10 mg methylphenidate (Mph). Those who had been on a stimulant dis-
continued the medication 48 hours before MRS imaging. Spectra were taken from the anterior 
cingulate cortex, dorsolateral prefrontal cortex, striatum, and cerebellum, and N-acetylaspartate 
(NAA), choline, and creatine levels were examined. For genotyping of the synapsin III gene 
polymorphisms, DNA was isolated from peripheral blood leukocytes. The effects of age, sex, 
and ADHD subtypes were controlled in the analyses.
Results: After a single dose of Mph, choline levels increased significantly in the striatum 
of rs133945G.A polymorphism-GG genotypes (P=0.020) and NAA levels rose in the 
anterior cingulate cortex of rs133946C.G polymorphism-CG genotypes (P=0.014). Both 
rs133945G.A and rs133946C.G polymorphisms were found to statistically significantly 
affect the alteration of NAA levels in response to Mph in dorsolateral prefrontal cortex with 
two-way repeated measure of analysis of variance. Post hoc comparisons revealed a significant 
difference between CG and GG genotypes of rs133946C.G polymorphisms after Bonferroni 
adjustment (P=0.016).
Conclusion: Synapsin III gene polymorphisms may be affecting the changes in neurometabo-
lite levels in response to Mph in adult ADHD patients. Future studies are needed to confirm 
our findings.
Keywords: adult ADHD, magnetic resonance spectroscopy, N-acetylaspartate, genotype
Introduction
Attention-deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder 
that is characterized by inattention, impulsiveness, and hyperactivity. The prevalence 
of ADHD is reported to be 7.2% in childhood and estimated to be 5% in adulthood.1,2 
Neuropsychological evaluations and structural and functional brain imaging studies 
have supported that ADHD is often characterized by structural and functional brain 
alterations in comparison to healthy controls.3 Similarly, ADHD treatment has been 
shown to cause alterations in brain regions by magnetic resonance imaging (MRI) 
studies. Methylphenidate (Mph) increases frontal and striatal metabolism as seen from 
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functional MRI scans.4 Long-term ADHD treatment with 
Mph was shown to normalize structural brain changes in the 
white matter, cerebellum, anterior cingulate cortex (ACC), 
and thalamus, and a single-dose of Mph has been found to 
increase the frontostriatal network for inhibitory control in 
ADHD-diagnosed children.4,5
Studies on ADHD etiology have used magnetic resonance 
spectroscopy (MRS) to investigate the possible neuro-
metabolic changes in the brain, which could be related to 
the pathogenesis of the disorder. MRS is a noninvasive 
method for measuring different metabolites including 
N-acetylaspartate (NAA), choline (Cho), creatine (Cr), and 
others in the human brain.6 NAA and Cr concentrations have 
been shown to be reduced in the left dorsolateral prefrontal 
cortex (DLPFC) in adult patients with ADHD.7,8 Colla et al9 
found increased Cho values in the ACC of adults diagnosed 
with ADHD.
The MRS technique also provides an opportunity for 
further investigations of metabolite changes in response 
to ADHD drug treatments. Studies conducted in children 
and adolescents have investigated the effect of acute or 
long-term ADHD treatment and have reported altered or 
unchanged neurometabolite levels.10–12 In adult patients 
with ADHD, increased NAA and reduced Cho levels in 
the anterior cingulum were reported following 5–6 weeks 
of Mph treatment.13 In another study, Maltezos et al found 
that adult ADHD patients had significantly lower concentra-
tions of glutamate + glutamine (Glx), Cr, and NAA in the 
basal ganglia and Cr in the DLPFC compared to controls. 
They showed no differences between treatment-naïve and 
stimulant-treated ADHD patients.8
In recent years, pharmacogenetic investigations 
have indicated the presence of a relationship between 
catecholaminergic-system-related genes and ADHD in 
children.14 However, in adults diagnosed with ADHD, 
most findings obtained in the pharmacogenetic area have 
been negative so far, and all of these studies focused on the 
response to Mph. Only one positive result was reported, 
which is for a polymorphism at the DAT1 gene.15 It has been 
suggested that the integration of neuroimaging methods and 
neuropsychological tests with these studies may be helpful 
in the understanding of the mechanisms of drug action and 
ADHD pathophysiology.15 But there are very few studies con-
ducted in this field. One study by Öner et al16 is an example, 
and the authors suggested that SNAP-25 genotypes (DdeI T/T 
and MnlI T/T) or (DdeI T/T and MnlI G/G or T/G) might be 
associated with Mph-induced brain hemodynamic changes 
in children with ADHD.
Dopamine is a clinically important neurotransmitter that 
has implications in many neuropsychiatric disorders includ-
ing ADHD.17 Synapsins (synapsin I, II, and III) are a family 
of three neuron-specific genes encoding for phosphoproteins, 
which have important roles in the regulation of neurodevel-
opment and neurotransmission.18 Among them, synapsin III 
has recently been demonstrated to be specifically involved 
in the release of dopamine in the striatum. To support this, 
Porton et al19 showed a similar magnitude of dopamine 
release in the slices derived from synapsin III knockout 
mice, suggesting that the regulation of dopamine release in 
the striatum is primarily related to synapsin III. Synapsin III 
polymorphism is mostly implicated in schizophrenia.20,21 
However, its association with ADHD has been studied only 
very rarely. Makkar et al22 failed to find a significant rela-
tion between synapsin III gene polymorphisms and ADHD. 
In contrast, Kenar et al23 found an association between 
the 631 C.G polymorphism of the synapsin III gene and 
ADHD in adult patients. As far as we know, the relationship 
between synapsin III polymorphisms and brain metabolites 
in response to Mph has not been investigated.
In this study, we aimed to investigate the alterations in 
neurometabolic variables according to synapsin III gene 
196 G.A (rs133945G.A) and 631 C.G (rs133946C.G) 
polymorphisms by using MRS, following the administration 
of a single dose of Mph, in DLPFC, ACC, striatum, and 
cerebellum in adult ADHD patients.
Methods
subjects
Fifty-seven voluntary adult patients 18–60 years of age and 
meeting criteria for ADHD according to Diagnostic and 
Statistical Manual of Mental Disorders, Fourth-Edition 
(DSM-IV), Text Revision24 participated in this study. 
The patients were recruited from the outpatient clinic 
of the Department of Psychiatry, Faculty of Medicine, 
Pamukkale University, Turkey. Illiterate patients or patients 
with any neurologic or chronic disorder, psychotic disorder, 
organic mental disorder, or mental retardation were excluded 
from the study. Ethical approvals were obtained from the 
Pamukkale University Ethics Committe. All the patients were 
informed about the aim and the procedures of the study, and 
signed written informed consents were obtained.
instruments
sociodemographic data form
This is a data sheet developed by the researchers for studying 
the sociodemographic characteristics of the study group.
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Adult Attention-Deficit Disorder/ADHD DSM-IV-
based diagnostic screening and rating scale
In the diagnostic assessment of patients, the Turkish version 
of Adult Attention-Deficit Disorder/ADHD DSM-IV based 
diagnostic screening and rating scales25,26 was used. When 
developing the adult Attention-Deficit Disorder/ADHD 
scale, 18 symptoms of the diagnostic criteria in DSM-IV 
were reframed so that patients could understand them. 
The first part of this scale had nine questions relating to 
inattention, and the second part also had nine questions on 
hyperactivity/impulsivity. The third part of the scale con-
sisted of the most frequently associated symptoms in ADHD 
that were not in the DSM-IV ADHD diagnostic criteria. 
Their Turkish validity and reliability were established by 
Günay et al.25
Mrs
Patients were examined by single-voxel 1H MRS, and 
spectra were taken from ACC, DLPFC, the striatum, and 
the cerebellum. A clinical 1.5 T MR scanner (GE Medical 
System, Milwaukee, WI, USA) was used with the following 
parameters: point-resolved spectroscopy sequence with water 
suppression (chemical-shift-selective imaging sequence), 
echo time/repetition time of 35/3,000 ms, and 128 averages. 
Conventional spin echo sequence with T2-weighted fast spin 
echo parameters were horizontal 10 mm slice thickness with 
repetition time/echo time 3,000/88, field-of-view (FOV): 
10 cm, matrix: 512×512, and next: 1. The whole Magnetic 
Resonance (MR) session took ~45 minutes.
Patients who had been on Mph treatment discontinued 
the medication 48 hours before the neuroimaging procedures. 
NAA, Cho, and Cr levels were examined by single-voxel 
1H MRS when medication naïve and 30 minutes after the 
administration of 10 mg oral Mph.
DNa isolation and molecular analysis
For the amplification of the synapsin III gene rs133945G.A 
polymorphism, DNA was isolated from peripheral blood 
leukocytes by the standard phenol/chloroform method and 
genotyped by the polymerase chain reaction (PCR)-restriction 
fragment length polymorphism method. PCR was performed 
with a personal thermal cycler (Techgene, NJ, USA) using 
SYN2 F-5′-T CCTTTCCAGAAGGATGTCC-3′/SYN2 
R-5 ′-AAGCCAACA AATACATAAGTGGAGA-3 ′ 
primers. For the amplification of the synapsin III gene 
rs133946C.G polymorphism, DNA was isolated from 
peripheral blood leukocytes by the standard phenol/
chloroform method and genotyped by the PCR-restriction 
fragment length polymorphism method. PCR was performed 
with a personal thermal cycler (Techgene) using SYN1 
F-5′-AGGCATGTACTTGCGTTACC-3′/SYN1 R-5′-
CCAAATGACTACAAAGATGTACCA-3′ primers.
statistical analysis
The findings of the study were analyzed with the SPSS 17.0 
package. The comparison of the categorical variables was 
made by Pearson’s chi-square test. The normality of dis-
persion of the numeric variables was evaluated with the 
Kolmogorov–Smirnov test. One-way analysis of variance 
(ANOVA) was used for three group comparisons of numeric 
variables. The significance of the neurometabolite level 
alterations before and after the medication was assessed by 
two related sample tests (paired-sample t-test). Statistical 
significance was accepted at the P,0.05 level. Two-way 
repeated measures of ANOVA were performed to compare 
the effects of single-dose Mph on brain metabolite levels 
between the genotypes of rs133945G.A and rs133946C.G 
polymorphisms of synapsin III gene while taking sex, age, 
and subtypes of ADHD as covariates. Outliers were con-
trolled. Post hoc comparisons were performed, Bonferroni 
correction was made, and P-value ,0.017 (0.05/3) was 
accepted as statistically significant.
Results
A total of 57 adult ADHD patients aged between 18 years 
and 60 years (12 women [21.1%] and 45 men [78.9%]; 
mean age: 29.05±7.85 years) were recruited for the study. 
Thirty-three (57.9%) of them had been on stimulant treatment 
for ADHD (Table 1).
Hardy–Weinberg equilibrium P-values for rs133945G.A 
and rs133946C.G were 0.674 (X2=0.175) and 0.501 (X2=0.452), 
Table 1 sociodemographic characteristics
n %
sex
Female 12 21.1
Male 45 78.9
Marital status
single 35 61.4
Married 18 31.6
Divorced 4 7.0
education
Primary education 5 8.8
high school 12 21.1
University 40 70.1
stimulant use
Yes 33 57.9
No 24 42.1
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respectively. For the rs133945G.A polymorphism, 30.4% 
(n=14) of the male participants had GG genotype, 47.8% 
(n=22) had GA genotype, and 21.7% (n=10) had AA genotype 
and 9.1% (n=1) of the female participants had GG genotype, 
72.7% (n=8) had GA genotype, and 18.2% (n=2) had AA 
genotype. For the rs133946C.G polymorphism, 28.3% 
(n=13) of the male participants had CC genotype, 50% (n=23) 
had CG genotype, and 21.7% (n=10) had GG genotype and 
9.1% (n=1) of the female participants had CC genotype, 
72.7% (n=8) had CG genotype, and 18.2% (n=2) had GG 
genotype. No significant difference was detected regarding the 
patients’ sex distribution according to synapsin III gene 196 
G.A polymorphism (X2=2.22, P=0.26) and synapsin III gene 
631 C.G polymorphism (X2=2.63, P=0.39). Age distribu-
tion was not statistically different among the GG (mean age 
32.1±10.2 years), GA (mean age 28.5±6.6 years), and AA 
(mean age 26.4±6.4 years) genotype groups of rs133945G.A 
polymorphism (F=2.35; P=0.10) and CC (mean age 
32.6±10.4 years), CG (mean age 28.4±6.5 years), and GG 
(mean age 26.4±6.3 years) genotype groups of rs133946C.G 
polymorphism (F=1,96; P=0.15). Age distribution was not 
statistically different among the GG, GA, and AA genotype 
groups of rs133945G.A polymorphism (F=2,35; P=0.10) and 
CC, CG, and GG genotype groups of rs133946C.G poly-
morphism (F=1,96; P=0.15). No significant difference was 
found regarding ADHD subtypes according to rs133945G.A 
polymorphism and rs133946C.G polymorphism (Table 2).
When we investigated the Cho levels, we found that 
its levels had increased significantly after a single dose of 
Mph in the striatum of rs133945G.A polymorphism-GG 
genotype (P=0.020). Another statistically significant dif-
ference was recorded for NAA values in the ACC of 
rs133946C.G polymorphism-CG genotype: after a single 
dose of 10 mg Mph, the NAA levels were found to have 
increased (P=0.014). In the other brain regions, we did not 
find any medication-related, statistically significant metabo-
lite level change in any of the polymorphism groups with 
paired sample t-test (Table 3).
The difference between rs133945G.A polymorphism 
GG, GA, and AA genotypes and rs133946C.G polymor-
phism CC, CG, and GG genotypes in terms of changes of 
NAA level was found to be statistically significantly differ-
ent in DLPFC with two-way repeated measure of ANOVA, 
while the sex, age, and subtypes of ADHD were taken as 
Table 2 Distribution of synapsin III genotypes among aDhD subtypes
Attention-deficit type, n (%) Combined type, n (%) Hyperactivity-impulsivity type, n (%) P-value*
rs133945g.a
gg 5 (33) 7 (47) 3 (20) 0.99
ga 11 (37) 14 (46) 5 (17)
aa 4 (33) 6 (50) 2 (17)
Total 20 (100) 27 (100) 10 (100)
rs133946c.g
cc 5 (36) 7 (50) 2 (14) 0.99
cg 11 (35) 14 (45) 6 (20)
gg 4 (33) 6 (50) 2 (17)
Total 20 (35.1) 26 (45.6) 11 (19.3)
Note: *chi-square test.
Abbreviation: ADHD, attention-deficit hyperactivity disorder.
Table 3 comparison of metabolites by genotype before and after methylphenidate
Metabolite Brain region Neurometobolite levels, mean ± SD P-value*
rs133945g.a GG GA AA
cho striatum
Before Mph 31.8±5.1a 35.9±6.9 37.8±7.2 α=0.020
after Mph 36.8±7.5a 37.0±7.4 39.5±9.4
rs133946c.g CC CG GG
Naa acc
Before Mph 64.7±14.1 65.1±14.6a 64.9±12.5 α=0.014
after Mph 67.3±12.1 69.2±12.9a 67.5±11.5
Notes: *Paired sample t-test; only the statistically significant results (P,0.05) are presented. aStatistical significance is obtained in the before and after Mph neurometobolite 
level comparisons.
Abbreviations: acc, anterior cingulate cortex; cho, choline; Mph, methylphenidate; Naa, N-acetylaspartate.
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covariates. Two outliers with CG and CC genotypes were 
detected and removed from the analysis.
The NAA values before the administration of Mph in the 
DLPFC were 63.6±9.9 in the GG genotype, 73.0±15.7 in the 
GA genotype, and 61.8±9.7 in the AA genotype. The values 
in the DLPFC post-Mph administration were 64.5±13.5 in the 
GG genotype, 74.9±16.0 in the GA genotype, and 62.7±7.2 
in the AA genotype. After controlling for the effects of age, 
sex, and ADHD subtypes, rs133945G.A polymorphism 
was found to be statistically significantly affecting the 
alteration of NAA levels in response to Mph in the DLPFC 
(F[2,49]=4,72; P=0.013; ɲ2=0.162). Post hoc comparisons 
were conducted to reveal the statistically significant 
group differences in the rs133945G.A genotypes, and 
GA and AA genotypes were found to be different regard-
ing the NAA levels (P=0.029). However, this difference 
was not found to be statistically significant according to 
Bonferroni adjustment.
The values of NAA in the DLPFC before Mph adminis-
tration were 64.5±9.5 in the CC genotype, 69.5±12.3 in the 
CG genotype, and 61.8±9.7 in the GG genotype. The corre-
sponding values of post-Mph administration were 65.5±13.4 
in the CC genotype, 71.4±12.8 in the CG genotype, and 
62.7±7.4 in the GG genotype. Similarly, when the effects 
of age, sex, and ADHD subtypes were controlled, rs133946 
C.G polymorphism was found to be statistically signifi-
cantly affecting the alteration of NAA levels in response to 
Mph in the DLPFC (F[2,51]=3,56; P=0.036; ɲ2=0.125). 
Post hoc comparisons revealed a statistically significant 
difference between CG and GG genotypes after Bonferroni 
adjustment (P=0.016; Figure 1). In the other brain regions, 
the polymorphism groups were not found to have any sta-
tistically significant effect on metabolite level alterations in 
response to Mph. The axial view of DLPFC and metabolite 
peaks are shown in Figure 2.
Discussion
In this study, we found that the variations of synapsin III 
gene rs133945G.A and rs133946C.G polymorphisms 
affected the NAA levels in the DLPFC after a single dose 
of Mph, while the age, sex, and ADHD subtypes were con-
trolled. In the post hoc tests, we could not find a statistically 
significant difference among the rs133945G.A genotypes. 
But regarding rs133946C.G genotypes, we found a signifi-
cant level of increase in the NAA concentrations for the CG 
genotype in comparison to the GG genotype.
To the best of our knowledge, this is the first study to 
investigate postmedication metabolite alterations among 
ADHD patients with regard to synapsin III polymorphism. 
Thus, we did not encounter any data that we could compare 
our results with regarding the impact of synapsin polymor-
phism genotypes on the medication-related neurometabolite 
alterations. Nevertheless, the NAA level alterations have 
been studied in relation to ADHD. Increased NAA levels in 
the PFC cortex of ADHD children have been reported.27–29 
It has been suggested that the increased levels might represent 
the compensatory increased metabolism based on “feedback 
mechanisms” in children in the PFC,30 or an indicator of 
hyperactivation in the resting state.29 On the other hand, 
Hesslinger et al have found decreased NAA levels in the 
left DLPFC of combined ADHD subtypes compared to 
inattentive subtypes and healthy controls in an MRS study 
in adults. The authors suggested that decreased NAA levels 
Figure 1 comparison of Naa changes by rs133946c.g genotypes before and 
after methylphenidate administration.
Abbreviations: DlPFc, dorsolateral prefrontal cortex; Mph, methylphenidate; 
Naa, N-acetylaspartate.
Figure 2 axial view of dorsolateral prefrontal cortex and a view of the metabolites’ 
resonance peaks.
Notes: The pale yellow circle demonstrates the dorsolateral prefrontal cortex 
region.
Abbreviations: cho, choline; Naa, N-acetylaspartate; tcr, total creatine.
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were associated with neuronal loss and neuronal function 
impairment.7 Husarova et al30 proposed that this finding 
might be related to the lower metabolism or decreased 
density of neurons due to the long-lasting hypermetabolism 
in the DLPFC. When we interpret these results together, it 
may be concluded that in children diagnosed with ADHD 
the NAA levels in the PFC may be increased in comparison 
with controls; however in adults, the differences in NAA 
levels between ADHD patients and healthy controls may 
disappear, or combined ADHD subtypes may have lower 
levels of NAA in comparison to controls.
A literature search revealed inconsistent data about 
the alterations in NAA levels in response to medications 
in ADHD patients: For example, Carrey et al31 treated 
children diagnosed with ADHD with atomoxetine, Mph, and 
dexedrine for 13 weeks and reported no significant change 
in NAA levels in response to medication in the PFCs of 
the participants. In another study conducted with children 
diagnosed with ADHD, again, Husarova et al reported 
decreased NAA levels and NAA/Cr ratio in the left DLPFC 
after 8 weeks of atomoxetine treatment but no change in 
response to Mph treatment.32 In contrast, Wiguna et al33 
found increased NAA/Cr ratio in the PFCs of children with 
ADHD after 20 mg daily Mph in their study and suggested 
that this change may be a result of functional amelioration 
and increase in neuroplasticity.
Our results regarding increased NAA concentrations after 
Mph administration are inconsistent with those of Wiguna 
et al.33 In the literature, it has been proposed that NAA is a 
marker of overall neuronal and axonal integrity, and while 
a low level of NAA is accepted as an indicator of neuronal 
loss and/or dysfunction, increased NAA may indicate 
neuroplasticity.7,10,30,33,34 Thus, increased NAA concentra-
tion in DLPFC that we reported may be an indicator of the 
alterations that contribute to the treatment effects of Mph. 
Microdialysis studies have demonstrated that clinically rel-
evant doses of Mph increase dopamine efflux preferentially 
within the PFC.35 Synapsin III is involved in slow synaptic 
transmission, particularly dopamine release,36 and it has a 
significant role in neurogenesis and axon formation.19 The 
impact of synapsin III polymorphism on the alterations of 
post-Mph DLPFC NAA levels that we have seen seems to 
be consistent with this knowledge. Based on this, we specu-
late that synapsin III gene may be one of the factors that 
contribute to the treatment effects of Mph in the DLPFC. 
It is unclear whether this effect is by the direct impact of 
synapsin III gene in the DLPFC or by indirect effects via 
striatofrontal networks. In a postmortem study conducted 
with schizophrenia patients, several synaptic proteins were 
found to be decreased in DLPFC, characterizing a synaptic 
pathology.37 More specifically, Porton and Wetsel38 reported 
reduced levels of synapsin III in schizophrenia patients. This 
data from the literature may lend support to the disturbances 
in synapsin III and other synaptic proteins especially in the 
DLPFC, which could be related to the pathogenesis of brain 
disorders. Hyman39 hypothesized that neural misconnectiv-
ity contributes to schizophrenia and other neuropsychiatric 
disorders, which is also in line with this view. There is need 
for future studies with animals and humans to find the answer 
to this question or to confirm this speculation.
According to post hoc comparisons, while there was 
no significant difference among the synapsin III gene 
rs133945G.A polymorphism genotypes, a statistical 
significance was detected between the rs133946C.G 
polymorphism genotypes: CG genotype was found to act to 
alter NAA concentrations more than the GG genotype. Kenar 
et al23 found in their study, which reported an association 
between ADHD and synapsin III gene rs133946C.G 
polymorphism, that the CG genotype was more frequent 
among ADHD patients and the GG genotype was more 
common among healthy controls. Thus, it may be suggested 
that, as indicated by increased NAA levels, an increase in 
post-Mph neuronal activation is more prominent among 
ADHD patients with the CG genotype in comparison to 
ADHD patients with the GG genotype. However, to confirm 
this view, more future studies are needed.
Another finding of our study was that NAA levels had 
significantly increased after a single dose of Mph in the ACC 
of rs133946C.G polymorphism CG genotype. Hammerness 
et al12 treated children diagnosed with ADHD for 6 weeks 
with Mph but could not find any significant change in the 
level of any metabolite, including NAA in the ACC of 
children. However, Kronenberg et al found a significant 
increase in NAA levels in the ACC of adult ADHD patients 
after administration of Mph for 5–6 weeks. They claimed 
that NAA is synthesized in the mitochondria in an energy-
dependent manner and is therefore regarded as an indicator 
of neuronal energy status.13 A study investigated the effect of 
Mph on hypoperfusion and reported that blood flow increased 
after the treatment in the bilateral prefrontal, caudate, and 
thalamic areas.40 Similarly, chronic Mph application was 
found to increase the neuronal mitochondrial activity in 
rats.41 Thus, our finding of increased NAA post-Mph may 
be an indicator of improved perfusion as well as increased 
neuronal activation in the CG genotype of rs133946C.G 
polymorphism.
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Finally, we found a significant increase in the Cho levels 
after a single dose of Mph in the striatum of patients with 
GG genotype of synapsin III gene rs133945G.A polymor-
phism. The Cho peak is considered to be related to membrane 
metabolism and believed to be reflecting membrane turnover, 
ie, either increased membrane degradation or synthesis.42,43 
Also the role of Cho-containing compounds has been indi-
cated in the energy metabolism,44,45 and a possible relationship 
to cholinergic neurotransmission has been suggested.46,47
Elevated Cho or Cho/Cr levels in the striatum, ACC, and 
PFC have been shown in patients with ADHD in comparison 
to controls.9,10,28,48 However, in a more recent meta-analysis, 
Aoki et al29 could not find a significant difference in Cho 
levels in the striatum of ADHD patients in comparison to 
controls. In studies searching for treatment effects, significant 
Cho and Cho/Cr decreases after 5–6 weeks of Mph treatments 
have been shown in the ACC in adults13 and in the PFC of 
children after 12 weeks of long-acting Mph.33
Findings of those studies that showed either elevated or 
unchanged Cho levels in ADHD patients or reduced levels 
after Mph treatment are in contrast to the increased Cho 
postmedication that we found. This difference could be a 
consequence of the medication (long acting vs short act-
ing, treatment duration, dose, etc) as well as the age, prior 
medication status of patients (treatment naïve or a prior 
history of medication use) or variable genetic structure of 
the participants. As support for probable medication-related 
alterations, it has been suggested that Mph may have differ-
ent acute effects on particular metabolites, and therefore, 
the reactivity rate of particular metabolites to drugs may 
be potentially different.32 Nonetheless, we should add that 
Husarova et al found increased Cho concentrations in the 
right DLPFC after atomoxetine medication but not Mph. The 
authors argued that, although this result was not in accordance 
with their hypothesis, increased Cho-containing compounds 
could indicate an increased membrane synthesis due to the 
restoration of membranes after the decrease in ADHD-
related hyperexcitation.32 In our study, the GG genotype of 
rs133945G.A polymorphism showed a trend toward hav-
ing markedly lower (although not at statistically significant 
level) premedication levels of Cho in comparison to other 
genotypes (Cho values for GG: 31.8±5, GA: 35.9±6.9, and 
AA: 37.8±7.2; P=0.056). Thus, we hypothesize, similar to 
Husarova et al, that in participants with the GG genotype, 
Mph might have acted to decrease the hyperexcitation, and 
as a consequence of the restoration of membranes, Cho syn-
thesis might have increased. The precise meaning of altered 
Cho signals needs to be resolved with future studies.48
Soliva et al found no significant correlations between 
dose or time duration of medication and neurometabolite 
levels in the frontal gyrus of pediatric ADHD subjects with 
an 18.2-month mean medication time.49 Similarly, in a study 
conducted with ADHD diagnosed children, one single dose 
of Mph had no significant effect on brain metabolite levels.10 
However, imaging studies have demonstrated the effect of 
a single dose and shown that Mph enhances attentional pro-
cessing and modulates the activity in brain areas associated 
with inhibition and attention. In line with this, short-term 
Mph and atomoxetine treatment were found to affect the 
neurometabolic changes in some studies.32,33,50,51 Also, Mph 
exposure has been reported to cause long-term changes in 
MRI studies.52,53
In the one study conducted with an adolescent age group, 
treated ADHD patients were found to have lower metabolite 
ratios in ACC than the untreated patients, although the dif-
ference was not statistically significant.12 In adult ADHD 
patients, increased NAA and reduced Cho levels in the 
anterior cingulum were reported following 5–6 weeks of Mph 
treatment.13 It has been suggested that the increase in NAA 
can be related to the induction of mitochondrial respiratory 
chain enzyme activities by chronic Mph exposure, especially 
in the PFC and striatum.41 However, Maltezos et al8 could not 
find any differences between treatment-naïve and stimulant-
treated ADHD patients. Collectively, although the results 
are controversial, Mph may have short-term and long-term 
effects in pediatric, adolescent, and adult ADHD patients. 
It should be kept in mind that 58% of our study participants 
had been on stimulant treatment and had not received medi-
cation in the last 48 hours.
To the best of our knowledge, this is the first study that 
investigated metabolite changes in the brain structure after a 
single dose of 10 mg Mph according to synapsin III polymor-
phisms in adult ADHD patients. The total number of patients 
who participated in the study was considerable when compared 
to previous studies. However, there are several limitations of 
the present study that should be noted. First, a good percentage 
of the patients had a prior history of long-term use of stimu-
lant medication, although a washout period of 48 hours was 
provided. This prior treatment might have affected the MRS 
metabolite levels. Second, cigarette smoking was not ruled 
out, which is a possible factor that might affect Mph response. 
Third, we did not correlate the metabolite changes with clinical 
outcome measures, such as neuropsychological tests. The 
fourth limitation is related to technical procedures: we used 
relatively low-Tesla MR and a unilateral area was evaluated. 
Finally, a control group was not present in the study.
 
N
eu
ro
ps
yc
hi
at
ric
 D
is
ea
se
 a
nd
 T
re
at
m
en
t d
ow
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
19
3.
25
5.
53
.2
03
 o
n 
21
-A
ug
-2
02
0
F
or
 p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Neuropsychiatric Disease and Treatment 2016:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1148
Başay et al
Conclusion
The results of this study suggest that synapsin III gene poly-
morphisms may be affecting the changes in neurometabolite 
levels in response to Mph in adult ADHD patients. Although 
the role of synaptic proteins in the etiopathogenesis of brain 
disorders has been shown in the literature, still there is need 
for more extensive and robust data. With future studies, the 
alterations in neurometabolite levels that are thought to be 
related to Mph response should be correlated with clinical 
improvement measures. While doing this, knowing the 
plasma concentrations of Mph may help in the interpretation 
of the findings and also contribute to a better understanding, 
at least, of some of the pharmacogenetic factors that have 
probable effects. Lastly, future studies should investigate age-
related alterations in child, adolescent, and adult age groups 
of participants to better understand the treatment responses 
and pathophysiology of ADHD.
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